Herb-drug interactions between the medicinal mushrooms Lingzhi and Yunzhi and cytotoxic anticancer drugs: a systematic review.
Anticancer drugs
Cytotoxic drugs
Herb–drug interaction
Lingzhi
Medicinal mushrooms
Yunzhi
Journal
Chinese medicine
ISSN: 1749-8546
Titre abrégé: Chin Med
Pays: England
ID NLM: 101265109
Informations de publication
Date de publication:
2020
2020
Historique:
received:
20
05
2020
accepted:
20
07
2020
entrez:
30
7
2020
pubmed:
30
7
2020
medline:
30
7
2020
Statut:
epublish
Résumé
Lingzhi and Yunzhi are medicinal mushrooms commonly used with cytotoxic chemotherapy in cancer patients in Asian countries. The current systematic review aims to identify potential pharmacokinetic or pharmacodynamic interactions from the existing literature to ensure their effective and safe combination usage in cancer patients. A systematic search was conducted on nine major Chinese and English databases, including China Journal Net, Allied and Complementary Medicine Database, and Ovid MEDLINE This search identified 213 studies, including 77 clinical studies that reported on the combined use of cytotoxic drugs with Yunzhi (n = 56) or Lingzhi (n = 21). Majority of these clinical studies demonstrated modest methodological quality. In clinical practice, the most commonly used cytotoxic drugs with Lingzhi were cisplatin, 5-fluorouracil (5-FU) and paclitaxel, whereas Tegafur/uracil (UFT)/Tegafur, 5-FU, and mitomycin were the ones used more often with Yunzhi. Only two clinical pharmacokinetic studies were available showing no significant interactions between Polysaccharide K (PSK) and Tegafur. From the pharmacodynamic interactions perspective, combination uses of Yunzhi/Lingzhi with cytotoxic drugs in clinical practice could lead to improvement in survival (n = 31) and quality of life (n = 17), reduction in tumor lesions (n = 22), immune modulation (n = 38), and alleviation of chemotherapy-related side effects (n = 14) with no reported adverse effects. Our findings suggest that the clinical combination use of Lingzhi or Yunzhi with cytotoxic drugs could enhance the efficacy and ameliorate the adverse effects of cytotoxic drugs, leading to improved quality of life in cancer patients. More high quality clinical studies including pharmacokinetic herb-drug interactions studies are warranted to verify these observations and mechanisms involved. Based on the high quality clinical data, pharmacoepidemiology methods and bioinformatics or data mining could be adopt for further identification of clinical meaningful herb-drug interactions in cancer therapies.
Sections du résumé
BACKGROUND
BACKGROUND
Lingzhi and Yunzhi are medicinal mushrooms commonly used with cytotoxic chemotherapy in cancer patients in Asian countries. The current systematic review aims to identify potential pharmacokinetic or pharmacodynamic interactions from the existing literature to ensure their effective and safe combination usage in cancer patients.
METHODS
METHODS
A systematic search was conducted on nine major Chinese and English databases, including China Journal Net, Allied and Complementary Medicine Database, and Ovid MEDLINE
RESULTS
RESULTS
This search identified 213 studies, including 77 clinical studies that reported on the combined use of cytotoxic drugs with Yunzhi (n = 56) or Lingzhi (n = 21). Majority of these clinical studies demonstrated modest methodological quality. In clinical practice, the most commonly used cytotoxic drugs with Lingzhi were cisplatin, 5-fluorouracil (5-FU) and paclitaxel, whereas Tegafur/uracil (UFT)/Tegafur, 5-FU, and mitomycin were the ones used more often with Yunzhi. Only two clinical pharmacokinetic studies were available showing no significant interactions between Polysaccharide K (PSK) and Tegafur. From the pharmacodynamic interactions perspective, combination uses of Yunzhi/Lingzhi with cytotoxic drugs in clinical practice could lead to improvement in survival (n = 31) and quality of life (n = 17), reduction in tumor lesions (n = 22), immune modulation (n = 38), and alleviation of chemotherapy-related side effects (n = 14) with no reported adverse effects.
CONCLUSION
CONCLUSIONS
Our findings suggest that the clinical combination use of Lingzhi or Yunzhi with cytotoxic drugs could enhance the efficacy and ameliorate the adverse effects of cytotoxic drugs, leading to improved quality of life in cancer patients. More high quality clinical studies including pharmacokinetic herb-drug interactions studies are warranted to verify these observations and mechanisms involved. Based on the high quality clinical data, pharmacoepidemiology methods and bioinformatics or data mining could be adopt for further identification of clinical meaningful herb-drug interactions in cancer therapies.
Identifiants
pubmed: 32724333
doi: 10.1186/s13020-020-00356-4
pii: 356
pmc: PMC7382813
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
75Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
Gan To Kagaku Ryoho. 2009 Nov;36(12):1972-4
pubmed: 20037295
J Biochem Biophys Methods. 1989 Mar;18(2):157-66
pubmed: 2501379
Oncol Lett. 2010 Jan;1(1):63-68
pubmed: 22966257
Cancer Sci. 2008 Jul;99(7):1461-70
pubmed: 18422750
J Agric Food Chem. 2011 Apr 27;59(8):3707-16
pubmed: 21381781
Jpn J Surg. 1982;12(4):244-8
pubmed: 6811786
Chin J Integr Med. 2019 Jan;25(1):71-79
pubmed: 30484022
Acta Pharmacol Sin. 2011 Dec;32(12):1505-12
pubmed: 22019957
Cancer Biother Radiopharm. 2009 Feb;24(1):35-40
pubmed: 19243246
Oncology. 1994 May-Jun;51(3):296-302
pubmed: 8196915
Oncol Lett. 2017 Nov;14(5):6066-6070
pubmed: 29113247
Chin Med. 2011 Jun 09;6:22
pubmed: 21651825
Jpn J Cancer Res. 1988 Jan;79(1):125-30
pubmed: 3128500
Lancet. 1994 May 7;343(8906):1122-6
pubmed: 7910230
J Surg Res. 2017 May 1;211:30-38
pubmed: 28501128
Am J Chin Med. 1997;25(1):27-35
pubmed: 9166995
Support Care Cancer. 2004 Jun;12(6):454-62
pubmed: 14991387
Recent Pat Inflamm Allergy Drug Discov. 2012 Jan;6(1):78-87
pubmed: 22185453
Control Clin Trials. 1996 Feb;17(1):1-12
pubmed: 8721797
Int J Oncol. 2011 May;38(5):1319-27
pubmed: 21399867
Immunopharmacol Immunotoxicol. 2008;30(4):771-82
pubmed: 18686097
Eur J Surg Oncol. 2015 Jun;41(6):795-800
pubmed: 25887287
Tokai J Exp Clin Med. 1981 Apr;6(2):141-6
pubmed: 7302997
J Agric Food Chem. 2010 Aug 11;58(15):8798-805
pubmed: 20681668
J Ethnopharmacol. 2007 May 4;111(2):219-26
pubmed: 17182202
Int J Immunopharmacol. 1988;10(4):445-50
pubmed: 3139576
Anticancer Drugs. 1991 Jun;2(3):275-8
pubmed: 1802023
Surg Today. 2018 Jan;48(1):66-72
pubmed: 28634730
Gan To Kagaku Ryoho. 2008 Nov;35(12):2283-5
pubmed: 19106597
J Cancer Res Clin Oncol. 2011 Jul;137(7):1117-22
pubmed: 21298288
Int J Oncol. 2015 May;46(5):2029-38
pubmed: 25779097
Gan. 1978 Apr;69(2):255-7
pubmed: 680463
Dis Colon Rectum. 2007 Aug;50(8):1169-81
pubmed: 17347903
Evid Based Complement Alternat Med. 2013;2013:219472
pubmed: 23662119
Cancer Immunol Immunother. 2011 Sep;60(9):1257-68
pubmed: 21553283
Cancer Res Treat. 2005 Oct;37(5):290-3
pubmed: 19956529
Int J Oncol. 2012 Apr;40(4):905-13
pubmed: 22159900
Anticancer Res. 2005 Mar-Apr;25(2B):1377-84
pubmed: 15865094
Br J Cancer. 2004 Mar 8;90(5):1003-10
pubmed: 14997197
Oncology. 1989;46(1):49-53
pubmed: 2492652
Anticancer Res. 2009 Mar;29(3):843-50
pubmed: 19414318
Jpn J Surg. 1990 Mar;20(2):127-36
pubmed: 2111414
Int J Oncol. 2008 Mar;32(3):689-99
pubmed: 18292947
Jpn J Surg. 1976 Jun;6(2):54-9
pubmed: 825677
Cancer Res. 1982 Dec;42(12):5176-80
pubmed: 7139621
Jpn J Surg. 1988 Nov;18(6):681-6
pubmed: 3150019
Mutat Res. 1989 May;226(1):9-12
pubmed: 2497345
Front Pharmacol. 2019 Jul 03;10:703
pubmed: 31333449
Food Chem Toxicol. 2006 May;44(5):689-94
pubmed: 16297519
Oncol Rep. 2013 Dec;30(6):2845-51
pubmed: 24100378
Front Microbiol. 2018 Dec 17;9:3099
pubmed: 30619178
Jinrui Idengaku Zasshi. 1980 Mar;25(1):15-21
pubmed: 7401377
PLoS One. 2013;8(4):e60338
pubmed: 23560092
Cancer Chemother Pharmacol. 1997;40(3):233-8
pubmed: 9219507
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2009 Apr;29(4):335-9
pubmed: 19526760
Oncology. 2008;74(3-4):143-9
pubmed: 18708731
Planta Med. 2012 Nov;78(16):1740-8
pubmed: 22961117
Am J Chin Med. 2005;33(5):807-15
pubmed: 16265993
Jpn J Surg. 1981;11(4):291-6
pubmed: 6793759
Int J Biol Macromol. 2014 Mar;64:395-401
pubmed: 24370474
Dis Colon Rectum. 1992 Feb;35(2):123-30
pubmed: 1735313
Cancer Biother. 1994 Winter;9(4):351-8
pubmed: 7719382
Medicine (Baltimore). 2016 Jul;95(27):e4115
pubmed: 27399116
Oncogene. 2003 Apr 10;22(14):2088-96
pubmed: 12687011
Oncology. 1991;48(6):498-504
pubmed: 1749590
Int J Biol Macromol. 2016 Oct;91:905-10
pubmed: 27208798
Oncol Rep. 2006 Apr;15(4):861-8
pubmed: 16525672
Immunopharmacol Immunotoxicol. 2013 Jun;35(3):426-33
pubmed: 23656432
Oncol Rep. 2017 Jan;37(1):594-600
pubmed: 27878254
Exp Toxicol Pathol. 2011 Jan;63(1-2):157-60
pubmed: 19962283
J Oncol Pract. 2017 Jul;13(7):e613-e622
pubmed: 28628392
J Cell Biochem. 2011 Mar;112(3):860-71
pubmed: 21328459
Kaohsiung J Med Sci. 2019 Apr;35(4):222-229
pubmed: 30958641
Biosci Biotechnol Biochem. 2008 Jun;72(6):1399-408
pubmed: 18540114
Int J Oncol. 2010 Mar;36(3):593-600
pubmed: 20126979
3 Biotech. 2012 Mar;2(1):1-15
pubmed: 22582152
Curr Drug Targets. 2011 May;12(5):621-30
pubmed: 21039338
Gan To Kagaku Ryoho. 1984 Sep;11(9):1843-7
pubmed: 6433806
Jpn J Surg. 1979 Jun;9(2):110-7
pubmed: 376911
Pancreatology. 2012 Nov-Dec;12(6):467-74
pubmed: 23217280
Gan To Kagaku Ryoho. 2017 Oct;44(10):896-899
pubmed: 29066688
Int J Clin Oncol. 2010 Apr;15(2):145-52
pubmed: 20229169
Chin Med. 2009 Dec 30;4:25
pubmed: 20042091
Cochrane Database Syst Rev. 2016 Apr 05;4:CD007731
pubmed: 27045603
Ann Intern Med. 2017 Jun 27;167(2):112-121
pubmed: 28654980
Jpn J Surg. 1982;12(3):203-7
pubmed: 7131965
Cancer Invest. 1995;13(4):363-9
pubmed: 7627722
Acta Pharmacol Sin. 2008 May;29(5):620-7
pubmed: 18430371
Jpn J Surg. 1983 Mar;13(2):112-6
pubmed: 6411956
Mutat Res. 2019 Sep;845:403065
pubmed: 31561886
Cancer Biother Radiopharm. 2008 Aug;23(4):461-7
pubmed: 18771350